乌鸦传媒

Possible guidance for use of adjuvant immunotherapy in high-risk, non-metastatic disease

Better OS, PFS, response rate, but newer combination strategies not included

More IKCS news: Long-term survival benefit with nivolumab/ipilimumab, disease-slowing surgery

Low rate of recurrence with surgery or nonsurgical options, but data can inform decisions

Confirmed responses in one-fourth to one-third of patients with refractory disease

Potential standard of care after current therapies, but key obstacles remain in the way

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

A quarter of patients responded whether at the recommended or higher dose

Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients

Thirteen-month survival gain falls short of statistical significance in observational study

Numerical advantage in median survival, response rate, durability with dendritic-cell agent

Nivolumab/ipilimumab achieves 1-year PFS of 100% in unresectable T1N0M0 tumors

Dramatic slowing of disease progression, prolonged responses with microbiome modulator

Present in roughly 5% of patients, survival worse in patients with larger or more lesions